Stock Movers: Merck, Lockheed Martin, Chewy (Podcast)

Merck (MRK) agreed to acquire Terns Pharmaceuticals for $6.7 billion to gain a promising leukemia treatment as it faces patent expiry on its top cancer drug. The Pentagon struck framework deals with Lockheed Martin and BAE to quadruple production of THAAD interceptor seekers, accelerating defense supply chains. Chewy (CHWY) shares rose after the company issued a fiscal 2027 net-sales forecast that beat the average analyst estimate.

Analysis

The MRK-related development materially shifts probability-weighted revenue for its oncology franchise over a 3–6 year horizon rather than tomorrow’s headline. The real lever is not just incremental top-line but the optionality it buys against an approaching patent trough: if the asset achieves label expansion and payer acceptance, a $1–2bn peak-sales stream within 4 years is realistic and would meaningfully offset royalty cliffs—conversely, a clinical/regulatory miss would crystallize downside quickly and compress multiple by 8–12%.

For prime defense contractors the short-run story is execution: accelerating production increases backlog visibility but also forces capacity reallocation, overtime and subcontractor mark-ups that can depress margins for 6–12 months before scale benefits emerge. The likely second-order winners are niche photonics, precision MEMS and advanced assembly suppliers whose revenues can double from baseline if qualification waves complete on schedule; the tail risk is supplier-single-sourcing and semiconductor constraints that could delay deliveries and push inflation into primes’ cost base.

Chewy’s guidance beat points to demand resilience and better unit economics, but the sustainability hinge is retention and margin mix (private label, shipping, advertising). If retention cohorts and AOV trends hold through two consecutive quarters, CHWY can re-rate towards higher growth multiples; if COGS or freight inflects upward, the stock will reprice within weeks rather than months.

Consensus is under-pricing execution and integration friction across the board: markets are rewarding headline-level outcomes while underestimating 6–12 month operational drag (overtime, supplier premiums, integration costs). Key reversals to watch are a major clinical data miss, a visible slowdown in DoD funding/contract cadence, or a quarter where Chewy’s gross margin reverts—each can flip the current bullish momentum rapidly.

Key Decisions for Investors

• Long MRK stock, 6–12 month horizon. Position size 2–3% portfolio; target 15–25% upside if oncology asset achieves commercial milestones and offsets patent erosion. Hedge with 1–2% notional 9–12 month MRK puts (8–10% OTM) to cap downside at ~8–12% on clinical or integration setbacks.
• Long LMT, 3–9 month horizon to capture re-rating from increased program awards and visible backlog. Size 2% portfolio; target 10–20% upside. Pair hedge: short BA (1:1 dollar exposure) if you want to isolate execution/production share gains versus peers—expect short-term margin pressure so use a 10% stop.
• Long CHWY into next two quarterly prints: buy shares or 6–9 month calls (slightly OTM). Size 1.5–2% portfolio; reward is 20–30% if retention/AOV trends persist and margins stabilize, downside 10–15% on margin reversion—use a 6–8% trailing stop or buy protective 3–6 month puts to limit drawdown.
• Directional supplier play: accumulate Tier-2 photonics/precision-assembly suppliers (defense supply-chain exposure) with 6–18 month horizon. Small position sizing (total 1–2% across names); upside from qualification waves is binary but large, downside limited to supply-chain cyclicality—monitor semiconductor lead times and DoD award calendars as primary catalysts.